We are CTA Health
The Canadian Technology Accelerator for Health in San Francisco exists to connect Canada’s up-and coming health and life sciences start-ups with potential investors, customers and strategic partners in Northern California. The program is led by the Consulate General of Canada in San Francisco and provides companies with curated access to one of the most important clusters of life sciences innovation in addition to the venture capital ecosystem and global technology hub of Silicon Valley.
CTA Health takes a customized approach to support entrepreneurs and their commercialization goals. Each CTA Health company is matched with a unique team of up to five world-class advisors specific to their business needs.
CTA Health is open to growth-stage companies from across Canada:
– With a minimum proof of concept and clear strategy for accessing the Bay Area market,
– Seeking venture capital [post-seed – series A] or alternative financing, partnerships, and customers within the next twelve months.
CTA Health uses a broad definition of health and life sciences, and is interested in working with a wide range of teams that are addressing unmet medical needs. Areas of focus include Biotechnology, Digital Health, Drug Discovery, Precision Medicine, Diagnostics, Genomics, Medical Devices, and Therapeutics.
At its core, CTA Health helps companies move farther, faster.
Companies
Weeks
Mentors
Equity Taken
CURRENT COMPANIES
-
AmacaThera
AmacaThera is a biotechnology company that develops advanced long acting injectable drug products based on a novel drug delivery hydrogel. The company’s first product is an extended-release non-opioid surgical pain management product.
-
BreatheSuite
BreatheSuite is a digital health company creating solutions to solve improper inhaler technique and adherence for patients with asthma and COPD. BreatheSuite’s mission is to develop self management devices that help respiratory patients live longer, healthier lives.
-
Fluid Biotech Inc.
Fluid Biotech has developed the world’s first bio-absorbable and self-expanding flow-diverting stent to heal blood vessels. The proprietary stent is specially designed to gently divert blood flow away from an aneurysm, thus allowing the blood vessel wall to heal and seal off the weakness.
-
MIMOSA Diagnostics
The Multispectral Mobile Tissue Assessment (MIMOSA) is a connected health care solution for patients with diabetes to non-invasively monitor their foot health. MIMOSA will allow for greater access to specialized care with the goal of preventing amputations and saving lives.
-
Optina Diagnostics
Perceiv AI is an artificial intelligence precision medicine company using proprietary machine learning algorithms to reinvent clinical trial patient selection and analysis. Through multiple partnerships, Perceiv AI is developing novel digital biomarkers to help clinical trials succeed by greatly improving treatment efficacy, cohort stratification and targeted patient selection.
-
Perceiv AI
Perceiv AI is an artificial intelligence precision medicine company using proprietary machine learning algorithms to reinvent clinical trial patient selection and analysis. Through multiple partnerships, Perceiv AI is developing novel digital biomarkers to help clinical trials succeed by greatly improving treatment efficacy, cohort stratification and targeted patient selection.
-
Picomole
Picomole is an medical device company that has developed novel, first in class hardware and software that applies machine learning (ML) to identify the presence of disease in breath accurately, affordably, and safely.
-
Specific Biologics Inc.
Specific Biologics’ gene editing platform technology Dualase overcomes two problems with current gene editors: random insertions and deletions; and low frequency DNA repair. With Dualase, Specific Biologics can target disease causing mutations that cannot be targeted by current technologies.
-
Vesalius Cardiovascular
Vesalius Cardiovascular has developed a unique solution to treat more than 95% of patients suffering from Degenerative Mitral Regurgitation, a heavily untreated and very common disease. Vesalius had created a device that adapts to fit any valve size and treats any diseased area of the heart valve by reproducing surgery with a catheter.
PARTNERSHIPS
CONTACT
